NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors. Ms. Thornberry, the Chief Executive Officer of Kallyope Inc., brings over 30 years of biopharma leadership to the board. Ms. Thornberry has received several awards for her scientific contributions, including the Merck Presidential Fellowship and Merck Directors Award, the Heroes of Chemistry Award from the American Chemical Society (ACS), the 2011 Thomas Alva Edison Patent Award from the Research and Development Council of New Jersey, and the 2011 Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award.
“Throughout her career, Nancy has been celebrated not only for her R&D breakthroughs, but for her leadership of both scientific and business strategies for biotech and pharmaceutical companies,” said Schrödinger CEO Ramy Farid, Ph.D. “As we expand our partnerships globally and grow our proprietary drug discovery pipeline, Nancy’s drug development experience and unique knowledge of the biopharma ecosystem will be an important asset for our board.”
Ms. Thornberry currently serves as the Chief Executive Officer of Kallyope, a platform biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis. In addition to her role at Kallyope, she serves as a Director at Intarcia Therapeutics. Prior to joining Kallyope, Ms. Thornberry served in roles of increasing responsibility at Merck & Co, Inc., including as Senior Vice President and Franchise Head, Diabetes and Endocrinology. In this role, Ms. Thornberry led discovery and clinical research across several therapeutic areas, including diabetes, osteoporosis, fertility, and contraception. During her career at Merck, Ms. Thornberry initiated and led multiple drug discovery and development programs, including Merck’s dipeptidyl peptidase 4 (DPP-4) inhibitor (marketed as JANUVIA®) for the treatment of Type 2 diabetes.
“This is an exciting time to join Schrödinger’s board, as the impact of the company’s computational platform continues to expand across the industry,” Ms. Thornberry said. “I look forward to working with the team to help guide the next phase of Schrödinger’s growth.”
About Schrödinger
Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide. In addition to this substantial and growing global business, Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit schrodinger.com for more information.
